Trial · NCT00918931
Obatoclax for Systemic Mastocytosis
NCT00918931, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2011-04-25
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Obatoclax for Systemic Mastocytosis. Trials, record NCT00918931. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00918931
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Obatoclax for Systemic Mastocytosis
- NCT number
- NCT00918931
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Leukemia, Systemic Mastocytosis
- Interventions
- Obatoclax Mesylate
- First posted
- 2009-06-11
- Last updated
- 2011-11-04
- Results first posted
- 2011-04-25
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rate | 3-Month Response Evaluation | Response rate is defined as number of participants with objective response divided by number of participants evaluated. Objective response is complete response and partial response where 'complete response' constitutes total elimination of a symptom or sign of the disease; 'partial response' constitutes at least 50% improvement in a symptom or sign of the disease. Objective response definitions of response evaluated following guidelines proposed by Valent et al. (International working group consensus criteria). |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rate | 3-Month Response Evaluation | Analysis was per protocol. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate | Obatoclax Mesylate | 0 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Obatoclax Mesylate | 3 | |
| Overall Study | COMPLETED | Obatoclax Mesylate | 3 | |
| Overall Study | NOT COMPLETED | Obatoclax Mesylate | 0 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anorexia | Gastrointestinal disorders | Obatoclax Mesylate | 2 | 3 | 2 |
| other | Ataxia | Nervous system disorders | Obatoclax Mesylate | 1 | 3 | 3 |
| other | Confusion | Nervous system disorders | Obatoclax Mesylate | 1 | 3 | 3 |
| other | Constipation | Gastrointestinal disorders | Obatoclax Mesylate | 1 | 3 | 1 |
| other | Dizziness | Nervous system disorders | Obatoclax Mesylate | 1 | 3 | 1 |
| other | Fatigue | General disorders | Obatoclax Mesylate | 2 | 3 | 5 |
| other | Injection site reaction | General disorders | Obatoclax Mesylate | 1 | 3 | 1 |
| other | Memory Impairment | Nervous system disorders | Obatoclax Mesylate | 1 | 3 | 1 |
| other | Nausea | Gastrointestinal disorders | Obatoclax Mesylate | 1 | 3 | 4 |
| other | Puritis | Skin and subcutaneous tissue disorders | Obatoclax Mesylate | 1 | 3 | 1 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Obatoclax Mesylate | ||
| Total, other adverse events | Obatoclax Mesylate | 3 | 3 |
| Total, serious adverse events | Obatoclax Mesylate | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00918931
GET https://conductscience.org/api/trials/v1/NCT00918931/registered